Cytogenetic investigations in two cases of anaplastic large cell lymphoma (ALCL) showed novel variants of the classical (2;5)(p23;q35) translocation, namely a t(1;2)(q21;p23) and a t(2;3)(p23;q21). The tumor cells in both cases gave positive immunohistochemical labeling for ALK protein (with both monoclonal and polyclonal antibodies), demonstrating that these translocations induce aberrant expression of this kinase and suggesting that genes other than NPM can activate the ALK gene in ALCL. These two cases were shown by an in vitro kinase assay to express ALK kinases (104 kD and 97 kD, respectively), which differed in size from the classical NPM-ALK fusion product (80 kD). Moreover, ALK expression was confined to the cytoplasm of the tumor cells in each case, supporting the hypothesis that the observed nuclear localization of NPM-ALK in classical ALCL is not the site of oncogenic activity of the ALK kinase.

ANAPLASTIC LARGE cell lymphoma (ALCL), first described by Stein et al,1 constitutes a subgroup of non-Hodgkin’s lymphoma characterized by unusual morphologic features and expression of the CD30 (Ki-1) antigen. Thirty percent to 40% of nodal ALCL carry the reciprocal t(2;5)(p23;q35) chromosomal translocation.2-4 This genetic abnormality juxtaposes theNPM gene at 5q35 to the ALK gene at 2p23,5leading to the generation of a novel chimeric NPM-ALK 80-kD kinase. ALK protein is not expressed in normal lymphocytes, and monoclonal and polyclonal anti-ALK antibodies (ALK1 and p80NPM/ALK) have therefore been widely used to provide immunohistochemical evidence for the presence of the NPM-ALK fusion protein in lymphoma cells.6 7 

Two cases of ALCL have been reported recently in which a positive immunohistochemical reaction for ALK protein was found in the absence of the t(2;5)(p23;q35) (as detected by classical cytogenetics).8,9 These cases were shown to carry variants of the classical t(2;5), namely a t(1;2)(q25;p23) and an inv(2)(p23q35). One further variant translocation, a t(2;13)(p23;q34), has been described by Sainati et al,10 although no immunohistochemical data are available on ALK expression.

We here report on two novel variant translocations in ALCL and additional immunohistochemical and in vitro kinase assay studies.

Patients.

Patient 1 was the 13-year-old boy D.F. who showed painful enlargement of cervical, axillary, and inguinal lymph nodes in June 1997. After diagnosis of a CD30+ ALCL of T-cell phenotype, he underwent chemotherapy according to the German NHL-BFM’95 protocol (group III/K3).11 After the final cycle the patient has remained in complete remission without symptoms.

A lymph node biopsy specimen obtained from patient 2 (10-year-old girl S.N.) in July 1994 showed a CD30+ ALCL of null cell phenotype. After initial chemotherapy (German NHL-BFM’90 protocol11) resulting in complete remission, a relapse occured in November 1995. Autologous bone marrow transplantation was performed in December 1995, and since then she is in complete remission.

Immunohistochemical and cytogenetic studies.

Immunohistochemical investigations on lymph node biopsy specimens included B- and T-cell markers, CD30 (BerH2), EMA, TIA-1, and the p80NPM/ALK 6 and ALK17 antibodies.

Cytogenetic analysis was performed on unstimulated short-term cultures of tumor tissue. Metaphases were stained by a conventional trypsin-Giemsa technique and evaluated according to the ISCN guidelines.12 

In vitro kinase assay.

Frozen tissue sections were subjected to an in vitro kinase assay technique that is detailed elsewhere.13 A frozen tumor of an ALCL-derived t(2;5)+ cell line SU-DHL-1 grown in severe combined immunodeficient (SCID) or nude mice and normal tonsils was used as positive and negative control.

Histological evaluation of the lymph node biopsy specimen from patient D.F. identified an ALCL of T-type with the tumor cells being positive for CD5, CD30, and TIA-1 and exhibiting strong cytoplasmic staining for ALK protein (with both the polyclonal antiserum p80NPM/ALKand the monoclonal antibody ALK1; Fig 1a).

Fig. 1.

(a) Section of a paraffin-embedded lymph node from patient D.F. stained for ALK1 expression (alkaline phophatase-technique). Large pleomorphic tumor cells show marked cytoplasmic but no nuclear immunostaining. (b) G-banded partial karyotype of patient D.F. exhibiting the translocation t(1;2)(q21;p23) (arrows). (c) G-banded partial karyotype of patient S.N. showing the t(2;3)(p23;q21) (arrows) and, additionally, a +del(3)(p21).

Fig. 1.

(a) Section of a paraffin-embedded lymph node from patient D.F. stained for ALK1 expression (alkaline phophatase-technique). Large pleomorphic tumor cells show marked cytoplasmic but no nuclear immunostaining. (b) G-banded partial karyotype of patient D.F. exhibiting the translocation t(1;2)(q21;p23) (arrows). (c) G-banded partial karyotype of patient S.N. showing the t(2;3)(p23;q21) (arrows) and, additionally, a +del(3)(p21).

Close modal

Cytogenetics showed a karyotype of 46,XY,t(1;2)(q21;p23)[12]/92,XXYY, t(1;2)(q21;p23)x2[4]/46,XY[1] (Fig 1b).

The lymph node biopsy specimen of S.N. led to the diagnosis of an ALCL of null cell phenotype. Again, strong cytoplasmic staining was noted for ALK protein (not shown). The karyotype, obtained from conventional cytogenetics, was: 47,XX,t(2;3)(p23;q21),+del(3)(p21)[5]/46,XX[3] (Fig 1c).

In the in vitro kinase assay, the most prominent phosphorylated proteins were a 104-kD band in the tumor from D.F. and a 97-kD band in cells from S.N. (for details see Fig 2).

Fig. 2.

Results from an in vitro kinase assay. Proteins were extracted from cryostat tissue sections, immunoprecipitated with anti-ALK, and incubated with radioactive kinase substrate. The samples were then resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by autoradiography. Phosphorylated proteins of 97 kD and 104 kD were detected in tumor tissue from patients S.N. and D.F., respectively. 80-kD phosphorylated NPM-ALK was present in the t(2;5)+ cell line SU-DHL-1. No ALK proteins were present in the tonsil lysates used as negative controls.

Fig. 2.

Results from an in vitro kinase assay. Proteins were extracted from cryostat tissue sections, immunoprecipitated with anti-ALK, and incubated with radioactive kinase substrate. The samples were then resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by autoradiography. Phosphorylated proteins of 97 kD and 104 kD were detected in tumor tissue from patients S.N. and D.F., respectively. 80-kD phosphorylated NPM-ALK was present in the t(2;5)+ cell line SU-DHL-1. No ALK proteins were present in the tonsil lysates used as negative controls.

Close modal

The t(2;5)(p23;q35) is regarded as a critical step in the genesis of nodal ALCL leading to the generation of a chimeric 80-kD NPM-ALK protein that is thought to cooperate in malignant transformation by aberrant activation of its ALK kinase domain.14-16 There is now clear evidence that the NPM-ALK fusion protein is directed from the cytoplasm to the nuclei of the tumor cells via heterodimerization with normal NPM.15,16 This results in the characteristic staining pattern for NPM-ALK in cells exhibiting the t(2;5)(p23;q35), in which both the nuclei and cytoplasm are labeled.7,16 17 

However, in a minority of ALCL cases, ALK protein expression is restricted to the cytoplasm of tumor cells.17,18 A possible interpretation of this staining pattern is the presence of chromosomal abnormalities affecting the ALK gene but not involvingNPM, and there is direct evidence for this in the report of a cytoplasmic distribution of ALK protein in an ALCL bearing a t(1;2)(q25;p23).7,16 Moreover, an ALK fusion protein in which NPM is replaced by a TPR sequence19 is capable of transforming cells in vitro and in vivo but is expressed only in the cytoplasm of transfected COS cells.15 16 

These results indicate that mechanisms other than the classical t(2;5) can lead to the activation of the ALK gene and that such cases should be recognizable because of their ‘cytoplasm-only’ pattern of ALK expression. Our two cases of ALCL carrying novel variant translocations support this suggestion. Furthermore, it was possible to show using an in vitro kinase assay that these variant translocations gave rise to ALK protein which differed in size from classical NPM-ALK (80 kD).5-7 The tumor carrying the t(1;2)(q21;p23) contained a 104-kD ALK protein and the t(2;3)(p23;q21) was associated with a 97-kD ALK protein.

Reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization techniques have also been applied to detect the classical t(2;5).9,20 21 Such procedures would not, however, have provided any information on variant translocations described in the present study. In view of this, the detection of ALK proteins using immunolabeling techniques combined with the in vitro kinase assay would seem to constitute the easiest way to provide evidence for novel ALK gene rearrangements in ALCL when cytogenetic data are not available.

It has recently been proposed that ALK+ lymphomas (‘ALKomas’) constitute a distinct clinicopathological entity.17 Variant translocations involving the ALKgene may permit the identification of new genes that could be involved in this entity. It will be of interest to see, with increasing experience, whether cases of ALCL with variant translocations behave biologically and/or clinically in a different way from cases of ‘ALKoma’ carrying the classical t(2;5).

The authors thank Heike Brückner, Andrea Trumpfheller, Maria Reichert, Sabine Roth, and Petra Stempfle for expert technical assistance.

Supported by the Deutsche Forschungsgemeinschaft, Sonderforschungsbereich 172, Teilprojekt C8 to G.O. and H.K.M.-H., and by the Leukaemia Research Fund, Grant No. 9646.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
Stein
H
Mason
DY
Gerdes
J
O’Connor
N
Wainscoat
J
Pallesen
G
Gatter
K
Falini
B
Delsol
G
Lemke
H
Schwarting
R
Lennert
K
The expression of Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.
Blood
66
1985
848
2
Le Beau
MM
Bitter
MA
Larson
RA
Doane
LA
Ellis
ED
Franklin
WA
Rubin
CM
Kadin
ME
Vardiman
JW
The t(2;5)(p23;q35): A recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma.
Leukemia
3
1989
866
3
Mason
DY
Bastard
C
Rimokh
R
Dastugue
N
Huret
JL
Kristofferson
U
Magaud
JP
Nezelof
C
Tilly
H
Vannier
JP
Hemet
J
Warnke
R
CD30-positive large cell lymphomas (‘Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35.
Br J Haematol
74
1990
161
4
Ott
G
Katzenberger
T
Siebert
R
DeCoteau
JF
Fletcher
JA
Knoll
JHM
Kalla
J
Rosenwald
A
Ott
MM
Weber-Matthiesen
K
Kadin
ME
Müller-Hermelink
HK
Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas.
Genes Chrom Cancer
22
1998
114
5
Morris
SW
Kirstein
MN
Valentine
MB
Dittmer
KG
Shapiro
DN
Saltman
DL
Look
AT
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma.
Science
263
1994
1281
6
Shiota
M
Fujimoto
J
Takenaga
M
Satoh
H
Ichinohasama
R
Abe
M
Nakano
M
Yamamoto
T
Mori
S
Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry.
Blood
84
1994
3648
7
Pulford
K
Lamant
L
Morris
SW
Butler
LH
Wood
KM
Stroud
D
Delsol
G
Mason
DY
Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
Blood
89
1997
1394
8
Lamant
L
Meggetto
M
Al Saati
T
Brugieres
L
Bressac de Paillerets
B
Dastugue
N
Bernheim
A
Rubie
H
Terrier-Lacombe
MJ
Robert
A
Brousset
P
Rigal
F
Schlaifer
D
Shiota
M
Mori
S
Delsol
G
High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin’s disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and p-80 immunostaining.
Blood
87
1996
284
9
Pittaluga
S
Wlodarska
I
Pulford
K
Campo
E
Morris
SW
Van den Berghe
H
De Wolf-Peeters
C
The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.
Am J Pathol
151
1997
343
10
Sainati
L
Montaldi
A
Stella
M
Putti
MC
Zanesco
L
Basso
G
A novel variant translocation t(2;13)(p23;q34) in Ki-1 large cell anaplastic lymphoma.
Br J Haematol
75
1990
621
11
Reiter
A
Schrappe
M
Parwaresch
R
Henze
G
Müller-Weihrich
S
Sauter
KW
Sykora
WD
Ludwig
H
Gadner
H
Riehm
H
Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—A report of the Berlin-Frankfurt-Münster group.
J Clin Oncol
13
1995
359
12
Mitelman
F
An International System for Human Cytogenetic Nomenclature.
1995
Karger
Basel, Switzerland
13
Pulford K, Falini B, Cordell J, Rosenwald A, Ott G, Müller-Hermelink HK, MacLennan KA, Delsol G, Campo E, Mason DY: Biochemical detection of novel ALK proteins in tissue sections of anaplastic large cell lymphoma. Am J Pathol (in press)
14
Fujimoto
J
Shiota
M
Iwahara
T
Seki
N
Satoh
H
Mori
S
Yamamoto
T
Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).
Proc Natl Acad Sci USA
93
1996
4181
15
Bischof
D
Pulford
K
Mason
DY
Morris
SW
Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
Mol Cell Biol
17
1997
2312
16
Mason
DY
Pulford
KAF
Bischof
D
Kuefer
MU
Butler
LH
Lamant
L
Delsol
G
Morris
SW
Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation.
Cancer Res
58
1998
1057
17
Benharroch
D
Meguerian-Bedoyan
Z
Lamant
L
Amin
C
Brugieres
L
Terrier-Lacombe
MJ
Haralambieva
E
Pulford
K
Pileri
S
Morris
SW
Mason
DY
Delsol
G
ALK-positive lymphoma: A single disease with a broad spectrum of morphology.
Blood
91
1998
2076
18
Falini
B
Bigerna
B
Frizzotti
M
Pulford
K
Pileri
S
Delsol
G
Carbone
A
Paulli
M
Magrini
U
Menestrina
F
Giardini
R
Pilotti
S
Mezzeloni
A
Ugolini
B
Billi
M
Pucciarini
A
Pelicci
P-G
Flenghi
L
ALK expression defines a distinct group of lymphomas (‘ALKomas’) with a wide morphologic spectrum.
Am J Pathol
153
1998
875
19
Rodrigues
GA
Park
M
Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase.
Mol Cell Biol
13
1993
6711
20
Weber-Matthiesen
K
Deerberg-Wittram
J
Rosenwald
A
Poetsch
M
Grote
W
Schlegelberger
B
Translocation t(2;5) is not a primary event in Hodgkin’s disease.
Am J Pathol
149
1996
463
21
Mathew
P
Sanger
WG
Weisenburger
DD
Valentine
M
Valentine
V
Pickering
D
Higgins
C
Hess
M
Cui
X
Srivastava
DK
Morris
SW
Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in Non-Hodgkin’s lymphoma by two-color fluorescence in situ hybridization.
Blood
89
1997
1678

Author notes

Address reprint requests to German Ott, MD, Pathologisches Institut der Universität, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany.

Sign in via your Institution